Author

Ashley A. Hart

Observed name: Ashley Hart

Institution: C4 Therapeutics (United States)

Observed institution: C4 Therapeutics (United States)

ORCID: 0000-0002-8663-4842

Observed ORCID: 0000-0002-8663-4842

OpenAlex ID: A5034603617

Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen–Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design

2021 · Scott J. Eron, Hongwei Huang, et al. · ACS Chemical Biology · 57

Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers

2022 · Katrina L. Jackson, Roman V. Agafonov, et al. · Cancer Research · 40

Development of an AchillesTAG degradation system and its application to control CAR-T activity

2021 · Gesine K. Veits, Christina S. Henderson, et al. · Current Research in Chemical Biology · 22

Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers

2022 · Mathew E. Sowa, Bridget Kreger, et al. · Cancer Research · 12

Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 10

Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models

2021 · James A. Henderson, R. Jason Kirby, et al. · Cancer Research · 10

Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma

2022 · James A. Henderson, Scott J. Eron, et al. · Cancer Research · 5

CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents

2022 · Samantha Perino, R. Jason Kirby, et al. · Blood · 4

Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 2

Works count: 9

Citation count: 162

H-index: 6

I10-index: 6